Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with different glucose metabolism status
Objectives Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. He...
Saved in:
Published in | Journal of endocrinological investigation Vol. 44; no. 4; pp. 781 - 790 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.04.2021
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1720-8386 0391-4097 1720-8386 |
DOI | 10.1007/s40618-020-01372-9 |
Cover
Abstract | Objectives
Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.
Methods
A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.
Results
Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL,
P
< 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974,
P
= 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568,
P
= 0.003).
Conclusion
GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations. |
---|---|
AbstractList | ObjectivesGlypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.MethodsA total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.ResultsSerum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003).ConclusionGPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations. Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.OBJECTIVESGlypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations.A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.METHODSA total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits.Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003).RESULTSSerum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003).GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations.CONCLUSIONGPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations. Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations. A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits. Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003). GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations. Objectives Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific phospholipase D (GPLD1) in an anchored site of the glycosylphosphatidylinositol, and then was released into the extracellular environment. Herein, we investigated the changes of serum GPC4 and GPLD1 levels in obese subjects with different glucose metabolism status and their relationship with adipose tissue insulin resistance index (Adipo-IR) in Chinese north populations. Methods A total of 221 obese subjects and 37 normal controls (NC) were recruited in this study. Obese subjects were divided into normal insulin (NI) group, hyperinsulinemia (HI) group, impaired glucose tolerance (IGT) group, and type 2 diabetes mellitus (DM) group. Serum GPC4, GPLD1, and adiponectin were determined by commercially available ELISA kits. Results Serum GPC4 levels in the HI, IGT, and DM groups were significantly higher than those in the NC and NI groups (2.27 ± 0.58 ng/mL, 2.21 ± 0.60 ng/mL, 2.49 ± 0.67 ng/mL vs. 1.70 ± 0.33 ng/mL, 1.93 ± 0.34 ng/mL, P < 0.05). GPC4 was positively correlated with GPLD1, which was the most important influencing factor of GPC4. Adipo-IR was independently and positively associated with serum GPC4 and GPLD1. For GPC4, after adjustment for confounders, the risk of adipose tissue insulin resistance in subjects with the highest tertile was 2.974-fold that of those with the lowest tertile (OR = 2.974, P = 0.013). For GPLD1, before adjustment for lipids, the increased probability still existed (Model 2, OR = 3.568, P = 0.003). Conclusion GPC4 is an adipokine associated with adipose tissue insulin resistance, and its activity may be regulated by GPLD1. GPC4 may be a marker for adipose tissue insulin resistance in Chinese north obese populations. |
Author | Yang, H. Gong, F. Zhang, K. Pan, H. Wang, L. Zhu, H. |
Author_xml | – sequence: 1 givenname: K. surname: Zhang fullname: Zhang, K. organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Department of Endocrinology, The First Hospital of Shijiazhuang City – sequence: 2 givenname: H. surname: Zhu fullname: Zhu, H. organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College – sequence: 3 givenname: L. surname: Wang fullname: Wang, L. organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College – sequence: 4 givenname: H. surname: Yang fullname: Yang, H. organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College – sequence: 5 givenname: H. orcidid: 0000-0003-2413-0646 surname: Pan fullname: Pan, H. email: panhui20111111@163.com organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College – sequence: 6 givenname: F. surname: Gong fullname: Gong, F. email: fygong@sina.com organization: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32816247$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstu1TAQhiNURC_wAiyQJTZsAr4ldpaoUECqxAJYR44z6fGRYwePAzqPx5vVh5SLuujKHvv7Z0Yz_3l1EmKAqnrO6GtGqXqDkrZM15TTmjKheN09qs6YKqEWuj35735anSPuKRVKaPWkOhVcs5ZLdVb9-gJpncmNPyzOmiCJCeMxshEPftlFXHYmu_HgXYjocvQ1LmDd5CzZfqN3i0Eg74iHH-CRmATEIEbrTIaR_HR5R8zollig7BBXIC7gWhKSBOgwm2CPTyQOUBBchz3YjJtwdNMECUIuPa32mGKGbIZSFGdSpHnFp9XjyXiEZ3fnRfXt6v3Xy4_19ecPny7fXtdWqCbXspXGMkk15UPH2mYYZSPa1rKulaCHlpWBTJJraQU3xnS0Gc1IeTeBAmm1EBfVqy3vkuL3FTD3s0ML3psAccWeS9GoRlHOC_ryHrqPawqlu0J1XaePayjUiztqHWYY-yW52aRD_2c5BeAbYFNETDD9RRjtjw7oNwf0xQH9bwf0XRHpeyLrypxcDDkZ5x-Wik2KpU64gfSv7QdUtziNyg4 |
CitedBy_id | crossref_primary_10_1016_j_clinbiochem_2023_110675 crossref_primary_10_1186_s40035_023_00341_5 crossref_primary_10_1002_jcp_31041 crossref_primary_10_1186_s43042_024_00572_9 crossref_primary_10_3389_fendo_2022_822221 crossref_primary_10_2147_PGPM_S463608 crossref_primary_10_3389_fonc_2022_1045995 crossref_primary_10_1016_j_ijcard_2022_08_018 crossref_primary_10_1080_10495398_2024_2374328 crossref_primary_10_1038_s41598_022_14306_7 crossref_primary_10_1161_ATVBAHA_124_321686 crossref_primary_10_1016_j_atherosclerosis_2022_02_015 |
Cites_doi | 10.1016/j.metabol.2008.11.021 10.1006/mgme.2001.3287 10.2337/dc13-0520 10.2337/db16-1167 10.1002/j.1460-2075.1994.tb06438.x 10.1002/hep.23116 10.1210/jcem-72-1-96 10.1016/j.metabol.2003.09.004 10.1126/science.2443973 10.3390/nu7115475 10.1210/jc.2012-4297 10.1111/jdi.12071 10.1007/s00018-007-7471-6 10.1056/NEJMra1011035 10.1182/blood.V83.8.2115.2115 10.1073/pnas.0601752103 10.1210/jc.2006-0075 10.1053/j.gastro.2007.04.068 10.1007/s00125-016-4024-2 10.1172/jci114142 10.1210/jc.2017-00047 10.1152/ajpendo.00319.2018 10.2337/db06-0263 10.1210/jc.2014-2018 10.1210/jc.2016-1376 10.2337/db11-1395 10.2337/dc13-0800 10.2337/diacare.26.12.3320 10.2337/dc18-S002 |
ContentType | Journal Article |
Copyright | Italian Society of Endocrinology (SIE) 2020 Italian Society of Endocrinology (SIE) 2020. |
Copyright_xml | – notice: Italian Society of Endocrinology (SIE) 2020 – notice: Italian Society of Endocrinology (SIE) 2020. |
DBID | AAYXX CITATION NPM K9. NAPCQ 7X8 |
DOI | 10.1007/s40618-020-01372-9 |
DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1720-8386 |
EndPage | 790 |
ExternalDocumentID | 32816247 10_1007_s40618_020_01372_9 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: No. 81673184; No. 81370898 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: National Key Program of Clinical Science grantid: WBYZ2011-873 – fundername: Natural Science Foundation of Beijing Municipality grantid: No. 7182130 funderid: http://dx.doi.org/10.13039/501100004826 – fundername: Natural Science Foundation of Beijing Municipality grantid: No. 7182130 – fundername: National Natural Science Foundation of China grantid: No. 81370898 – fundername: National Natural Science Foundation of China grantid: No. 81673184 |
GroupedDBID | --- -EM .GJ 0R~ 203 4.4 406 53G 5GY 5RE 8RF 8YF 96X AACDK AAEWM AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAZMS ABAKF ABDZT ABECU ABFTV ABHLI ABIPD ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABTEG ABTKH ABTMW ABXPI ACAOD ACDTI ACGFS ACHSB ACKNC ACMLO ACOKC ACPIV ACPRK ACUDM ACZOJ ADHHG ADINQ ADJJI ADKNI ADKPE ADURQ ADYFF ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEODN AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFQWF AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHSBF AI. AIAKS AIGIU AILAN AITGF AJBLW AJRNO AJZVZ AKLTO AKMHD ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH ASPBG AUKKA AVWKF AXYYD AZFZN BGNMA CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FYJPI GGCAI GGRSB GJIRD GQ7 GRRUI HG6 HRMNR I0C IKXTQ IMOTQ ITM IWAJR J-C JBSCW JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O93 O9G O9J P2P PT4 RHV RLLFE ROL RSV SCLPG SDE SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE TSG U9L UG4 UOJIU UTJUX UZXMN VFIZW VH1 W48 Z7U Z83 Z87 ZGI ZMTXR ZOVNA ZXP AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION NPM ABRTQ K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c375t-464ac140802b9165bd45366c1964e8b61162f4284c32aaa905dad029fe7e4c833 |
IEDL.DBID | AGYKE |
ISSN | 1720-8386 0391-4097 |
IngestDate | Thu Sep 04 19:41:05 EDT 2025 Fri Jul 25 10:02:57 EDT 2025 Thu Apr 03 06:56:35 EDT 2025 Tue Jul 01 02:10:49 EDT 2025 Thu Apr 24 23:07:52 EDT 2025 Fri Feb 21 02:48:56 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Obesity Adipose tissue insulin resistance (adipo-IR) Glypican4 (GPC4) Adiponectin (ADP) Glycosylphosphatidylinositol-specific phospholipase D (GPLD1) |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c375t-464ac140802b9165bd45366c1964e8b61162f4284c32aaa905dad029fe7e4c833 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-2413-0646 |
PMID | 32816247 |
PQID | 2499987387 |
PQPubID | 2043718 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2435757022 proquest_journals_2499987387 pubmed_primary_32816247 crossref_primary_10_1007_s40618_020_01372_9 crossref_citationtrail_10_1007_s40618_020_01372_9 springer_journals_10_1007_s40618_020_01372_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-04-01 |
PublicationDateYYYYMMDD | 2021-04-01 |
PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: Italy – name: Heidelberg |
PublicationSubtitle | Official Journal of Italian Society of Endocrinology (SIE) |
PublicationTitle | Journal of endocrinological investigation |
PublicationTitleAbbrev | J Endocrinol Invest |
PublicationTitleAlternate | J Endocrinol Invest |
PublicationYear | 2021 |
Publisher | Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
References | Shulman (CR4) 2014; 371 Mahendran, Cederberg, Vangipurapu, Kangas, Soininen, Kuusisto, Uusitupa, Ala-Korpela, Laakso (CR28) 2013; 36 Scherer (CR7) 2006; 55 von Toerne, Huth, de Las Heras Gala, Kronenberg, Herder, Koenig, Meisinger, Rathmann, Waldenberger, Roden, Peters, Thorand, Hauck (CR20) 2016; 59 Ussar, Bezy, Bluher, Kahn (CR11) 2012; 61 Groop, Saloranta, Shank, Bonadonna, Ferrannini, DeFronzo (CR25) 1991; 72 Saponaro, Gaggini, Carli, Gastaldelli (CR1) 2015; 7 Zhu, Pan, Cui, Wang, Wang, Li, Yang, Gong (CR13) 2014; 99 Raikwar, Bowen-Deeg, Du, Low, Deeg (CR17) 2010; 59 Gastaldelli, Harrison, Belfort-Aguilar, Hardies, Balas, Schenker, Cusi (CR6) 2009; 50 Chalasani, Vuppalanchi, Raikwar, Deeg (CR21) 2006; 91 Gastaldelli, Cusi, Pettiti, Hardies, Miyazaki, Berria, Buzzigoli, Sironi, Cersosimo, Ferrannini, Defronzo (CR26) 2007; 133 Masuda, Fujishima, Maeda, Tsugawa-Shimizu, Nakamura, Tanaka, Obata, Fukuda, Nagao, Kita, Nishizawa, Shimomura (CR15) 2019; 316 Fico, Maina, Dono (CR10) 2011; 68 Metz, Brunner, Choi-Muira, Nguyen, Gabrilove, Caras, Altszuler, Rifkin, Wilson, Davitz (CR14) 1994; 13 Gastaldelli, Gaggini, DeFronzo (CR3) 2017; 66 Kurtz, Fineberg, Considine, Deeg (CR19) 2004; 53 Sondergaard, Espinosa De Ycaza, Morgan-Bathke, Jensen (CR5) 2017; 102 Hershkop, Besor, Santoro, Pierpont, Caprio, Weiss (CR9) 2016; 101 Tamori, Kasuga (CR8) 2013; 4 Yoo, Hwang, Cho, Hong, Choi, Hwang, Kim, Bluher, Youn, Baik, Choi (CR29) 2013; 98 Schofield, Stephens, Hurel, Bell, deSouza, Rademacher (CR18) 2002; 75 Brunner, Metz, Nguyen, Gabrilove, Patel, Davitz, Rifkin, Wilson (CR22) 1994; 83 Ascaso, Pardo, Real, Lorente, Priego, Carmena (CR23) 2003; 26 Groop, Bonadonna, DelPrato, Ratheiser, Zyck, Ferrannini, DeFronzo (CR2) 1989; 84 CR24 Gesta, Bluher, Yamamoto, Norris, Berndt, Kralisch, Boucher, Lewis, Kahn (CR12) 2006; 103 Davitz, Hereld, Shak, Krakow, Englund, Nussenzweig (CR16) 1987; 238 Defronzo, Tripathy, Schwenke, Banerji, Bray, Buchanan, Clement, Henry, Kitabchi, Mudaliar, Ratner, Stentz, Musi, Reaven, Gastaldelli (CR27) 2013; 36 S Ussar (1372_CR11) 2012; 61 C von Toerne (1372_CR20) 2016; 59 LC Groop (1372_CR2) 1989; 84 RA Defronzo (1372_CR27) 2013; 36 A Gastaldelli (1372_CR6) 2009; 50 Y Tamori (1372_CR8) 2013; 4 G Brunner (1372_CR22) 1994; 83 CN Metz (1372_CR14) 1994; 13 S Masuda (1372_CR15) 2019; 316 NS Raikwar (1372_CR17) 2010; 59 HJ Yoo (1372_CR29) 2013; 98 PE Scherer (1372_CR7) 2006; 55 C Saponaro (1372_CR1) 2015; 7 GI Shulman (1372_CR4) 2014; 371 MA Davitz (1372_CR16) 1987; 238 TA Kurtz (1372_CR19) 2004; 53 HJ Zhu (1372_CR13) 2014; 99 N Chalasani (1372_CR21) 2006; 91 E Sondergaard (1372_CR5) 2017; 102 1372_CR24 JN Schofield (1372_CR18) 2002; 75 LC Groop (1372_CR25) 1991; 72 JF Ascaso (1372_CR23) 2003; 26 K Hershkop (1372_CR9) 2016; 101 S Gesta (1372_CR12) 2006; 103 A Gastaldelli (1372_CR26) 2007; 133 Y Mahendran (1372_CR28) 2013; 36 A Gastaldelli (1372_CR3) 2017; 66 A Fico (1372_CR10) 2011; 68 |
References_xml | – volume: 59 start-page: 1413 issue: 10 year: 2010 end-page: 1420 ident: CR17 article-title: Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance publication-title: Metabolism doi: 10.1016/j.metabol.2008.11.021 – volume: 75 start-page: 154 issue: 2 year: 2002 end-page: 161 ident: CR18 article-title: Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats publication-title: Mol Genet Metab doi: 10.1006/mgme.2001.3287 – volume: 36 start-page: 3607 issue: 11 year: 2013 end-page: 3612 ident: CR27 article-title: Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk publication-title: Diabetes Care doi: 10.2337/dc13-0520 – volume: 66 start-page: 815 issue: 4 year: 2017 end-page: 822 ident: CR3 article-title: Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio Metabolism Study publication-title: Diabetes doi: 10.2337/db16-1167 – volume: 13 start-page: 1741 issue: 7 year: 1994 end-page: 1751 ident: CR14 article-title: Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D publication-title: EMBO J doi: 10.1002/j.1460-2075.1994.tb06438.x – volume: 50 start-page: 1087 issue: 4 year: 2009 end-page: 1093 ident: CR6 article-title: Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis publication-title: Hepatology (Baltimore, MD) doi: 10.1002/hep.23116 – volume: 72 start-page: 96 issue: 1 year: 1991 end-page: 107 ident: CR25 article-title: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem-72-1-96 – volume: 53 start-page: 138 issue: 2 year: 2004 end-page: 139 ident: CR19 article-title: Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D publication-title: Metabolism doi: 10.1016/j.metabol.2003.09.004 – volume: 238 start-page: 81 issue: 4823 year: 1987 end-page: 84 ident: CR16 article-title: A glycan-phosphatidylinositol-specific phospholipase D in human serum publication-title: Science (New York, NY) doi: 10.1126/science.2443973 – volume: 7 start-page: 9453 issue: 11 year: 2015 end-page: 9474 ident: CR1 article-title: The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis publication-title: Nutrients doi: 10.3390/nu7115475 – volume: 98 start-page: 2897 issue: 7 year: 2013 end-page: 2901 ident: CR29 article-title: Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-4297 – volume: 4 start-page: 250 issue: 3 year: 2013 end-page: 251 ident: CR8 article-title: Glypican-4 is a new comer of adipokines working as insulin sensitizer publication-title: J Diabetes Invest doi: 10.1111/jdi.12071 – volume: 68 start-page: 923 issue: 6 year: 2011 end-page: 929 ident: CR10 article-title: Fine-tuning of cell signaling by glypicans publication-title: Cell Mol Life Sci CMLS doi: 10.1007/s00018-007-7471-6 – volume: 371 start-page: 1131 issue: 12 year: 2014 end-page: 1141 ident: CR4 article-title: Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease publication-title: N Engl J Med doi: 10.1056/NEJMra1011035 – volume: 83 start-page: 2115 issue: 8 year: 1994 end-page: 2125 ident: CR22 article-title: An endogenous glycosylphosphatidylinositol-specific phospholipase D releases basic fibroblast growth factor-heparan sulfate proteoglycan complexes from human bone marrow cultures publication-title: Blood doi: 10.1182/blood.V83.8.2115.2115 – volume: 103 start-page: 6676 issue: 17 year: 2006 end-page: 6681 ident: CR12 article-title: Evidence for a role of developmental genes in the origin of obesity and body fat distribution publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0601752103 – volume: 91 start-page: 2279 issue: 6 year: 2006 end-page: 2285 ident: CR21 article-title: Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic fatty liver disease: a preliminary study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2006-0075 – volume: 133 start-page: 496 issue: 2 year: 2007 end-page: 506 ident: CR26 article-title: Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.068 – volume: 59 start-page: 1882 issue: 9 year: 2016 end-page: 1892 ident: CR20 article-title: MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study publication-title: Diabetologia doi: 10.1007/s00125-016-4024-2 – volume: 84 start-page: 205 issue: 1 year: 1989 end-page: 213 ident: CR2 article-title: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance publication-title: J Clin Investig doi: 10.1172/jci114142 – volume: 102 start-page: 1193 issue: 4 year: 2017 end-page: 1199 ident: CR5 article-title: How to measure adipose tissue insulin sensitivity publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2017-00047 – volume: 316 start-page: E239 issue: 2 year: 2019 end-page: E250 ident: CR15 article-title: Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00319.2018 – volume: 55 start-page: 1537 issue: 6 year: 2006 end-page: 1545 ident: CR7 article-title: Adipose tissue: from lipid storage compartment to endocrine organ publication-title: Diabetes doi: 10.2337/db06-0263 – volume: 99 start-page: E2697 issue: 12 year: 2014 end-page: 2701 ident: CR13 article-title: The changes of serum glypican4 in obese patients with different glucose metabolism status publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-2018 – volume: 101 start-page: 2423 issue: 6 year: 2016 end-page: 2431 ident: CR9 article-title: Adipose insulin resistance in obese adolescents across the spectrum of glucose tolerance publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-1376 – volume: 61 start-page: 2289 issue: 9 year: 2012 end-page: 2298 ident: CR11 article-title: Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine publication-title: Diabetes doi: 10.2337/db11-1395 – volume: 36 start-page: 3732 issue: 11 year: 2013 end-page: 3738 ident: CR28 article-title: Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men publication-title: Diabetes Care doi: 10.2337/dc13-0800 – ident: CR24 – volume: 26 start-page: 3320 issue: 12 year: 2003 end-page: 3325 ident: CR23 article-title: Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism publication-title: Diabetes Care doi: 10.2337/diacare.26.12.3320 – volume: 36 start-page: 3607 issue: 11 year: 2013 ident: 1372_CR27 publication-title: Diabetes Care doi: 10.2337/dc13-0520 – volume: 133 start-page: 496 issue: 2 year: 2007 ident: 1372_CR26 publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.068 – volume: 102 start-page: 1193 issue: 4 year: 2017 ident: 1372_CR5 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2017-00047 – volume: 99 start-page: E2697 issue: 12 year: 2014 ident: 1372_CR13 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-2018 – volume: 103 start-page: 6676 issue: 17 year: 2006 ident: 1372_CR12 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0601752103 – volume: 66 start-page: 815 issue: 4 year: 2017 ident: 1372_CR3 publication-title: Diabetes doi: 10.2337/db16-1167 – volume: 371 start-page: 1131 issue: 12 year: 2014 ident: 1372_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMra1011035 – volume: 59 start-page: 1413 issue: 10 year: 2010 ident: 1372_CR17 publication-title: Metabolism doi: 10.1016/j.metabol.2008.11.021 – volume: 75 start-page: 154 issue: 2 year: 2002 ident: 1372_CR18 publication-title: Mol Genet Metab doi: 10.1006/mgme.2001.3287 – volume: 50 start-page: 1087 issue: 4 year: 2009 ident: 1372_CR6 publication-title: Hepatology (Baltimore, MD) doi: 10.1002/hep.23116 – volume: 7 start-page: 9453 issue: 11 year: 2015 ident: 1372_CR1 publication-title: Nutrients doi: 10.3390/nu7115475 – volume: 13 start-page: 1741 issue: 7 year: 1994 ident: 1372_CR14 publication-title: EMBO J doi: 10.1002/j.1460-2075.1994.tb06438.x – volume: 61 start-page: 2289 issue: 9 year: 2012 ident: 1372_CR11 publication-title: Diabetes doi: 10.2337/db11-1395 – volume: 55 start-page: 1537 issue: 6 year: 2006 ident: 1372_CR7 publication-title: Diabetes doi: 10.2337/db06-0263 – volume: 98 start-page: 2897 issue: 7 year: 2013 ident: 1372_CR29 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-4297 – volume: 4 start-page: 250 issue: 3 year: 2013 ident: 1372_CR8 publication-title: J Diabetes Invest doi: 10.1111/jdi.12071 – volume: 36 start-page: 3732 issue: 11 year: 2013 ident: 1372_CR28 publication-title: Diabetes Care doi: 10.2337/dc13-0800 – volume: 101 start-page: 2423 issue: 6 year: 2016 ident: 1372_CR9 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-1376 – ident: 1372_CR24 doi: 10.2337/dc18-S002 – volume: 68 start-page: 923 issue: 6 year: 2011 ident: 1372_CR10 publication-title: Cell Mol Life Sci CMLS doi: 10.1007/s00018-007-7471-6 – volume: 26 start-page: 3320 issue: 12 year: 2003 ident: 1372_CR23 publication-title: Diabetes Care doi: 10.2337/diacare.26.12.3320 – volume: 91 start-page: 2279 issue: 6 year: 2006 ident: 1372_CR21 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2006-0075 – volume: 84 start-page: 205 issue: 1 year: 1989 ident: 1372_CR2 publication-title: J Clin Investig doi: 10.1172/jci114142 – volume: 59 start-page: 1882 issue: 9 year: 2016 ident: 1372_CR20 publication-title: Diabetologia doi: 10.1007/s00125-016-4024-2 – volume: 83 start-page: 2115 issue: 8 year: 1994 ident: 1372_CR22 publication-title: Blood doi: 10.1182/blood.V83.8.2115.2115 – volume: 53 start-page: 138 issue: 2 year: 2004 ident: 1372_CR19 publication-title: Metabolism doi: 10.1016/j.metabol.2003.09.004 – volume: 316 start-page: E239 issue: 2 year: 2019 ident: 1372_CR15 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00319.2018 – volume: 72 start-page: 96 issue: 1 year: 1991 ident: 1372_CR25 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem-72-1-96 – volume: 238 start-page: 81 issue: 4823 year: 1987 ident: 1372_CR16 publication-title: Science (New York, NY) doi: 10.1126/science.2443973 |
SSID | ssj0037387 |
Score | 2.370045 |
Snippet | Objectives
Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific... Glypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific... ObjectivesGlypican4 (GPC4) is a novel adipokine associated with obesity and insulin resistance. GPC4 was cleaved by the glycosylphosphatidylinositol-specific... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 781 |
SubjectTerms | Adiponectin Adipose tissue Diabetes mellitus (non-insulin dependent) Endocrinology Glucose Glucose metabolism Glucose tolerance Glycosylphosphatidylinositol Heparan sulfate proteoglycans Hyperinsulinemia Insulin Insulin resistance Internal Medicine Lipids Medicine Medicine & Public Health Metabolic Diseases Metabolism Obesity Original Article Phospholipase D |
Title | Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with different glucose metabolism status |
URI | https://link.springer.com/article/10.1007/s40618-020-01372-9 https://www.ncbi.nlm.nih.gov/pubmed/32816247 https://www.proquest.com/docview/2499987387 https://www.proquest.com/docview/2435757022 |
Volume | 44 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgKyEuvB8LpTISN0iV2E7iHFvoUoHaEyuVU-RXYEU2iZrksPw7_hkziRMEBaQeE48TJzOeh_3NmJBXkhVS20IGMKlVIKyMA_ASeAC2r-CFDY0bTm84O09O1-LDRXzhk8LaCe0-bUkOmnpOdkPTIwMMd7BMHguym2QvjmQmF2Tv6P3njyeTBsZiPalPkPl7z9-N0BXP8squ6GBsVnfJehrmiDH5dth3-tB8_6OC43W_4x65471PejSKy31yw1UPyK0zv7_-kPwA1dFv6Zdy16B6FFRVFq9M3e4Qxd42X4GTdgfvRbBXXQaYqYloIzq21uWmAbtI39ES0UgtVZeOKi8CzlJc9qXKbpoaiLqB6dTD4SkE_ujMghTCLVprByRtr3GhqB07Tqe5dNQj7enWdSDF5abdUkyN6ttHZL06-fT2NPCHPASGp3EXiEQoA1GeDJkGVzXWVsQ8SQwWCnNSJ1GUsAJiJGE4U0plYWyVDVlWuNQJIzl_TBZVXbmnhMbGpJhrbJTmQqeJdhCBR5mKi8SGhWNLEk1cz42vgI4HcZT5XLt54E0OvMkH3uTZkrye-zRj_Y__Uu9PwpR7XdDmDINKiTK5JC_nZpjFuDWjKlf3SMPBb07BoVqSJ6MQzq_jTMI_END7zSRQvx7-77E8ux75c3KbIVxnACXtk0V32bsX4G91-gCm1-r4-PzAT7Ofdg8n3Q |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgK0EvvCkLBYzEDVJlbSdxjhW0LLTbU1cqp8ivwIrsJmqSw_Lv-GfMJE4QFJB6TDxOnMx4HvY3Y0JeS5ZLbXMZwKRWgbAyCsBL4AHYvpznNjSuO71hcRbPl-LTRXThk8LqAe0-bEl2mnpMdkPTIwMMd7BMHgvSm2RHQAweTsjO4YfPJ0eDBsZiPYlPkPl7z9-N0BXP8squaGdsju-S5TDMHmPy7aBt9IH5_kcFx-t-xz1yx3uf9LAXl_vkhts8ILcWfn_9IfkBqqNd0y_FtkL1KKjaWLwyZb1FFHtdfQVO2i28F8FeZRFgpiaijWjfWharCuwifU8LRCPVVF06qrwIOEtx2Zcqu6pKIGo6plMPh6cQ-KMzC1IIt2ipHZDUrcaForrvOJzm0lCPtKdr14AUF6t6TTE1qq0fkeXx0fm7eeAPeQgMT6ImELFQBqI8GTINrmqkrYh4HBssFOakjmezmOUQIwnDmVIqDSOrbMjS3CVOGMn5YzLZlBv3hNDImARzjY3SXOgk1g4i8Fmqojy2Ye7YlMwGrmfGV0DHgziKbKzd3PEmA95kHW-ydErejH2qvv7Hf6n3B2HKvC6oM4ZBpUSZnJJXYzPMYtyaURtXtkjDwW9OwKGakr1eCMfXcSbhHwjo_XYQqF8P__dYnl6P_CW5PT9fnGanH89OnpFdhtCdDqC0TybNZeueg-_V6Bd-qv0E_j8pPg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgK1VceFMWChiJG7jN2s7rWNEuhdKKA5XKKfIrsCKbRJvksPw7_hkzibM8CkiI4ybjrHf92fNN_M2YkGcJzxNt84TBpFZM2iRkwBIEA9-Xi9wGxvWnN5yeRcfn8s1FePFDFn-vdh-3JIecBqzSVLb7tc33N4lv6IYShqEPlszjLL1KtmQA5H9Ctg5efTg5GldjLNwT-2SZ37f82SFdYpmXdkh7xzO_QdTY5UFv8nmva_We-fJLNcf_-U03yXXPSunBAKNb5Iorb5PtU7_vfod8hSWlW9KPxbrGZVNSVVr8ZKpmjer2pv4EI2zX0AcUgVUFwwxOVCHR4W5VLGrwl_SQFqhSaqhaOao8NJyl-DqYKruoKzBqezBQL5OnK9cgyQV0wiVaaQcmTafxBVIzNBxPeWmpV-DTpWsB3cWiWVJMmeqau-R8fvT-5THzhz8wI-KwZTKSykD0lwRcA4UNtZWhiCKDBcRcoqPZLOI5xE7SCK6USoPQKhvwNHexkyYR4h6ZlFXp7hMaGhNjDrJRWkgdR9pBZD5LVZhHNsgdn5LZiIDM-MroeEBHkW1qOvdjk8HYZP3YZOmUPN-0qYe6IH-13h2Blfk1osk4BpsJ4nNKnm5uw-zGLRtVuqpDGwF8OgaiNSU7AyA3Xyd4Av-BhNYvRnB9f_if-_Lg38yfkO13h_Ps7euzk4fkGkdFT69b2iWTdtW5R0DJWv3Yz7pvX2oyIg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+glypican4+and+glycosylphosphatidylinositol-specific+phospholipase+D+levels+are+associated+with+adipose+tissue+insulin+resistance+in+obese+subjects+with+different+glucose+metabolism+status&rft.jtitle=Journal+of+endocrinological+investigation&rft.au=Zhang%2C+K.&rft.au=Zhu%2C+H.&rft.au=Wang%2C+L.&rft.au=Yang%2C+H.&rft.date=2021-04-01&rft.issn=1720-8386&rft.eissn=1720-8386&rft.volume=44&rft.issue=4&rft.spage=781&rft.epage=790&rft_id=info:doi/10.1007%2Fs40618-020-01372-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s40618_020_01372_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8386&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8386&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8386&client=summon |